🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Rituximab and Ocrelizumab in Serum With Multiple Sclerosis

Recruitingn/aAges 18 Years - 60 YearsAllHaukeland University Hospital
NCT06663111 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

ROS-MS is a clinical pharmacological substudy to the OVERLORD-MS study (NCT04578639), designed to examine the possibilities of personalized treatment with rituximab and ocrelizumab in patients with relapsing-remitting multiple sclerosis.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Included in OVERLORD-MS (NCT04578639) * Willing to attend laboratory for blood sample collection at scheduled time points Exclusion criteria: \* Not willing to attend laboratory for blood sample collection at scheduled time points
💊

What it tests

  • Blood samples for PK
  • Blood samples for PK
📍

Where

1 site
Haukeland University Hospital, Deparment of medical biochemistry and pharmacology
Bergen, Norway
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy